157 related articles for article (PubMed ID: 30026012)
1. Outcomes of pancreatic adenocarcinoma that was not resected because of isolated para-aortic lymph node involvement.
Marchese U; Ewald J; Gilabert M; Delpero JR; Turrini O
J Visc Surg; 2019 Apr; 156(2):97-101. PubMed ID: 30026012
[TBL] [Abstract][Full Text] [Related]
2. Benefit of Gemcitabine/Nab-Paclitaxel Rescue of Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma After Early Failure of FOLFIRINOX.
Vreeland TJ; McAllister F; Javadi S; Prakash LR; Fogelman DR; Ho L; Varadhachary G; Aloia TA; Vauthey JN; Lee JE; Kim MP; Katz MHG; Tzeng CD
Pancreas; 2019 Jul; 48(6):837-843. PubMed ID: 31210666
[TBL] [Abstract][Full Text] [Related]
3. Outcomes of Primary Chemotherapy for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma.
Maggino L; Malleo G; Marchegiani G; Viviani E; Nessi C; Ciprani D; Esposito A; Landoni L; Casetti L; Tuveri M; Paiella S; Casciani F; Sereni E; Binco A; Bonamini D; Secchettin E; Auriemma A; Merz V; Simionato F; Zecchetto C; D'Onofrio M; Melisi D; Bassi C; Salvia R
JAMA Surg; 2019 Oct; 154(10):932-942. PubMed ID: 31339530
[TBL] [Abstract][Full Text] [Related]
4. Nanoliposomal irinotecan plus fluorouracil and folinic acid as a second-line treatment option in patients with metastatic pancreatic ductal adenocarcinoma: a retrospective cohort study.
Park SJ; Kim H; Shin K; Hong TH; Suh JH; Lee MA
BMC Cancer; 2021 Nov; 21(1):1176. PubMed ID: 34732161
[TBL] [Abstract][Full Text] [Related]
5. Positive para-aortic lymph nodes following pancreatectomy for pancreatic cancer. Systematic review and meta-analysis of impact on short term survival and association with clinicopathologic features.
Agalianos C; Gouvas N; Papaparaskeva K; Dervenis C
HPB (Oxford); 2016 Aug; 18(8):633-41. PubMed ID: 27485057
[TBL] [Abstract][Full Text] [Related]
6. Intraoperative frozen section analysis of para-aortic lymph nodes after neoadjuvant FOLFIRINOX: will it soon become useless?
Garnier J; Magallon C; Ewald J; Palen A; Marchese U; Delpero JR; Turrini O
Langenbecks Arch Surg; 2022 May; 407(3):1065-1071. PubMed ID: 34705107
[TBL] [Abstract][Full Text] [Related]
7. Prognostic impact of para-aortic lymph node status in resected pancreatic ductal adenocarcinoma and invasive intraductal papillary mucinous neoplasm - Time to consider a reclassification?
Linder S; Holmberg M; Engstrand J; Ghorbani P; Sparrelid E
Surg Oncol; 2022 May; 41():101735. PubMed ID: 35287096
[TBL] [Abstract][Full Text] [Related]
8. Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma.
Kaufmann B; Hartmann D; D'Haese JG; Stupakov P; Radenkovic D; Gloor B; Friess H
Dig Surg; 2019; 36(6):455-461. PubMed ID: 30408790
[TBL] [Abstract][Full Text] [Related]
9. Common Hepatic Artery Abutment or Encasement Is an Adverse Prognostic Factor in Patients with Borderline and Unresectable Pancreatic Cancer.
Kozak GM; Epstein JD; Deshmukh SP; Scott BB; Keith SW; Lavu H; Yeo CJ; Winter JM
J Gastrointest Surg; 2018 Feb; 22(2):288-294. PubMed ID: 29139084
[TBL] [Abstract][Full Text] [Related]
10. FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel for Neoadjuvant Treatment of Resectable and Borderline Resectable Pancreatic Head Adenocarcinoma.
Dhir M; Zenati MS; Hamad A; Singhi AD; Bahary N; Hogg ME; Zeh HJ; Zureikat AH
Ann Surg Oncol; 2018 Jul; 25(7):1896-1903. PubMed ID: 29761331
[TBL] [Abstract][Full Text] [Related]
11. Clinical application of the biomarkers for the selection of adjuvant chemotherapy in pancreatic ductal adenocarcinoma.
Oba A; Ban D; Kirimura S; Akahoshi K; Mitsunori Y; Matsumura S; Ochiai T; Kudo A; Tanaka S; Minoru T
J Hepatobiliary Pancreat Sci; 2016 Aug; 23(8):480-8. PubMed ID: 27247050
[TBL] [Abstract][Full Text] [Related]
12. Neoadjuvant FOLFIRINOX for borderline resectable pancreas cancer: a new treatment paradigm?
Christians KK; Tsai S; Mahmoud A; Ritch P; Thomas JP; Wiebe L; Kelly T; Erickson B; Wang H; Evans DB; George B
Oncologist; 2014 Mar; 19(3):266-74. PubMed ID: 24569947
[TBL] [Abstract][Full Text] [Related]
13. Failure to Undergo Resection Following Neoadjuvant Therapy for Resectable Pancreatic Cancer: A Secondary Analysis of SWOG S1505.
Cloyd JM; Colby S; Guthrie KA; Lowy AM; Chiorean EG; Philip P; Sohal D; Ahmad S
J Natl Compr Canc Netw; 2024 Apr; 22(4):. PubMed ID: 38688309
[TBL] [Abstract][Full Text] [Related]
14. Preoperative risk factors for para-aortic lymph node positivity in pancreatic cancer.
Okada K; Uemura K; Kondo N; Sumiyoshi T; Seo S; Otsuka H; Serikawa M; Ishii Y; Tsuboi T; Murakami Y; Takahashi S
Pancreatology; 2021 Apr; 21(3):606-612. PubMed ID: 33648880
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of para-aortic lymph node metastasis in pancreatic ductal adenocarcinoma.
Murakami Y; Uemura K; Sudo T; Hashimoto Y; Yuasa Y; Sueda T
World J Surg; 2010 Aug; 34(8):1900-7. PubMed ID: 20376442
[TBL] [Abstract][Full Text] [Related]
16. The Proteomic Landscape of Pancreatic Ductal Adenocarcinoma Liver Metastases Identifies Molecular Subtypes and Associations with Clinical Response.
Law HC; Lagundžin D; Clement EJ; Qiao F; Wagner ZS; Krieger KL; Costanzo-Garvey D; Caffrey TC; Grem JL; DiMaio DJ; Grandgenett PM; Cook LM; Fisher KW; Yu F; Hollingsworth MA; Woods NT
Clin Cancer Res; 2020 Mar; 26(5):1065-1076. PubMed ID: 31848187
[TBL] [Abstract][Full Text] [Related]
17. Survival impact of distal pancreatectomy with en bloc celiac axis resection combined with neoadjuvant chemotherapy for borderline resectable or locally advanced pancreatic body carcinoma.
Murakami Y; Nakagawa N; Kondo N; Hashimoto Y; Okada K; Seo S; Otsuka H
Pancreatology; 2021 Apr; 21(3):564-572. PubMed ID: 33526385
[TBL] [Abstract][Full Text] [Related]
18. A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy.
Kaissis G; Ziegelmayer S; Lohöfer F; Steiger K; Algül H; Muckenhuber A; Yen HY; Rummeny E; Friess H; Schmid R; Weichert W; Siveke JT; Braren R
PLoS One; 2019; 14(10):e0218642. PubMed ID: 31577805
[TBL] [Abstract][Full Text] [Related]
19. Prognostic Impact of Para-Aortic Lymph Node Micrometastasis in Pancreatic Ductal Adenocarcinoma.
Komo T; Murakami Y; Kondo N; Uemura K; Hashimoto Y; Nakagawa N; Urabe K; Takahashi S; Sueda T
Ann Surg Oncol; 2016 Jun; 23(6):2019-27. PubMed ID: 26856722
[TBL] [Abstract][Full Text] [Related]
20. A single center experience in resectable pancreatic ductal adenocarcinoma : the limitations of the surgery-first approach. Critical review of the literature and proposals for practice update.
Dumont R; Puleo F; Collignon J; Meurisse N; Chavez M; Seidel L; Gast P; Polus M; Loly C; Delvenne P; Meunier P; Hustinx R; Deroover A; Detry O; Louis E; Martinive P; Van Daele D
Acta Gastroenterol Belg; 2017; 80(4):451-461. PubMed ID: 29560639
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
